Article
HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice.
Immunity - 10 Mar 2026
Galvez Nicolas M S, Nitido Adam D, Yoo Seo Bin, Cao Yi, Deal Cailin E, Boutros Christine L, MacDonald Scott W, Soto Albrecht Yentli E, Lam Evan C, Sheehan Maegan L, Parsons Dylan, Lin Allen Z, Deymier Martin J, Brady Jacqueline M, Moon Benjamin, Bullock Christopher B, Tanno Serah, Pegu Amarendra, Chen Xuejun, Liu Cuiping, Koup Richard A, Mascola John R, Vrbanac Vladimir D, Lingwood Daniel, Balazs Alejandro B
Abstract excerpt
Broadly neutralizing antibodies (bNAbs) have shown promise for the prevention and treatment of HIV. Potency and breadth measured in vitro are often used as predictors of clinical potential; however, human studies demonstrate that the clinical efficacy of bNAbs can be undermined by both preexisting and de novo resistance. Here, we found that HIV-infected humanized mice receiving bNAbs delivered via...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
